Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Shivering is recognized as an undesirable effect of spinal anesthesia. Patients undergoing gynecological surgeries may experience increased physiological stress due to perioperative shivering. This condition can lead to serious complications such as increased oxygen consumption, resulting in hypoxemia, lactic acidosis, and elevated carbon dioxide production. Additionally, shivering may cause increased intraocular and intracerebral pressure and can interfere with monitoring techniques like pulse oximetry, blood pressure, and electrocardiography. If not treated, shivering can negatively impact patient outcomes, prolong recovery times, and extend hospital stays. The use of opioids has shown effectiveness in treating shivering. Based on the existing literature, it is hypothesized that there is no difference in the efficacy of nalbuphine and ketamine in controlling perioperative shivering in patients undergoing gynecological surgery under spinal anesthesia. Therefore, the study aims to investigate and compare the effectiveness of nalbuphine and ketamine in managing post-spinal shivering in these patients, focusing on i) incidence of shivering, ii) severity of shivering in both groups, iii) complications such as vomiting and sedation, and iv) the need for rescue medication. Preventing and managing shivering is crucial for successful surgical outcomes. To date, no comparative study has evaluated the intravenous efficacy of these two drugs in this patient population for post-spinal shivering control. This will be a double-blind, randomized controlled trial conducted in the Anesthesiology Department at DHQ Teaching Hospital Sargodha. A total of 90 gynecological patients will be enrolled and divided equally into two groups: Group N receiving nalbuphine and Group K receiving ketamine. Parameters such as heart rate, systolic and diastolic blood pressure, temperature, oxygen saturation, incidence and grade of shivering, complications like sedation and vomiting, and the need for rescue medication will be recorded. The study may face limitations due to the lack of advanced monitoring equipment for assessing parameters like core body temperature at the study site. Evaluations of cognitive and psychomotor functions cannot be conducted due to resource constraints. The use of a non-probability convenience sampling method, while practical, may introduce bias. Additionally, precise blinding may not be achievable due to limited technical personnel, and financial constraints prevent increasing the sample size.
Shivering, a repetitive involuntary muscular activity, is the most common problem during and after spinal anesthesia. The spinal anesthesia not only causes vasodilation, resulting in rapid loss of heat, but it also causes redistribution of heat in the peripheral areas, resulting in hypothermia and, eventually, shivering. Although it does not result in death, complications can arise in patients with a history of cardiorespiratory diseases, endangering the patients' safety. These complications include hypoxemia with increased lactic acidosis and carbon dioxide, increased oxygen consumption, increased intraocular and intracerebral pressure resulting in aggravation of post-operative pain and increased surgical bleeding that interferes with pulse rate and ECG monitoring.
Various treatments are currently available to control shivering in patients following spinal anesthesia. These include both pharmacological and non-pharmacological methods. Non-pharmaceutical methods are effective but expensive. A variety of pharmacological methods for controlling post-spinal anesthesia shivering have been suggested, including ketamine and nalbuphine as well as many others that are inexpensive and easy to use. Ketamine, a competitive receptor antagonist of N-methyl D-aspartate (NMDA), is known to reduce regional anesthesia by 70% and postoperative shivering by impairing thermoregulatory controls. It causes vasoconstriction in patients at risk of hypothermia. Ketamine controls shivering through non-shivering thermogenesis, either through the β-adrenergic effect of norepinephrine or through the hypothalamus. Nalbuphine, a semi-synthetic "class B" opioid analgesic, has both K-agonist and µ-antagonist properties. It has a high affinity for K-opioid receptors in the central nervous system. In the hypothalamus, the temperature regulation threshold is lowered by it for vasoconstriction during shivering due to the presence of high-density a2 adeno-receptors. The anti-shivering effects of intravenous ketamine and nalbuphine are poorly understood. Therefore, a double-blind, placebo-controlled, randomized study has been designed to compare the potency and efficacy of ketamine with nalbuphine and investigate the possible control mechanisms in patients undergoing gynecological surgery receiving spinal anesthesia.
The objectives of this study are to investigate and compare the effects of nalbuphine and ketamine in patients undergoing spinal anesthesia for gynecological surgeries in terms of:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants assigned to this arm received injection nalbuphine. | Experimental | After spinal anesthesia in a sitting position at L3-L4 or L4-L5 using a 25-gauge Quincke spinal needle, 1.2 mL of 0.75% (7.5 mg) hyperbaric bupivacaine was injected in the subarachnoid space. The Bromage scale and cold test by using a spirit swab will be used to evaluate the subarachnoid block for the desired motor and sensory blocks, respectively. After spinal anesthesia, the study drug Nalbuphin (0.07 mg/kg) will be administered intravenously to group N, and oxygen will be given through a face mask at 4 liters per minute. |
|
| Participants assigned to this arm received injection Ketamine. | Experimental | After spinal anesthesia in a sitting position at L3-L4 or L4-L5 using a 25-gauge Quincke spinal needle, 1.2 mL of 0.75% (7.5 mg) hyperbaric bupivacaine was injected into the subarachnoid space. The Bromage scale and cold test by using a spirit swab will be used to evaluate the subarachnoid block for the desired motor and sensory blocks, respectively. After spinal anesthesia, the study drug ketamine (0.2 mg/kg) will be administered intravenously to group N, and oxygen will be given through a face mask at 4 liters per minute. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Participants assigned to this arm received injection nalbuphine. | Drug | After spinal anesthesia in a sitting position at L3-L4 or L4-L5 using a 25-gauge Quincke spinal needle, 1.2 mL of 0.75% (7.5 mg) hyperbaric bupivacaine was injected in the subarachnoid space. The Bromage scale and cold test by using a spirit swab will be used to evaluate the subarachnoid block for the desired motor and sensory blocks, respectively. After spinal anesthesia, the study drug Nalbuphin (0.07 mg/kg) will be administered intravenously to group N, and oxygen will be given through a face mask at 4 liters per minute. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of shivering in both study groups | Shivering will be assessed by the presence or absence of shivering. | Within one hour post-spinal anesthesia. |
| Grades of shivering | Shivering will be assessed by Tsai and Chu, with the grade of shivering as follows: Grade of shivering: clinical sign 0 No shivering
| After spinal anesthesia, grades of shivering were assessed at 5 minutes and then after every 10 minutes until 60 minutes. |
| Measure | Description | Time Frame |
|---|---|---|
| Heart rate | Heart rate will be monitored by a pulse oximeter probe. | After spinal anesthesia, heart rate will be assessed at 5 minutes and then after every 10 minutes until 60 minutes. |
| Oxygen Saturation |
| Measure | Description | Time Frame |
|---|---|---|
| Need of Rescue drug | If the grade of shivering is ≥3, then 0.5 mg/kg of injection tramadol will be administered intravenously as a second rescue plan to control shivering in both study groups. | Within one hour post-spinal anesthesia. |
Inclusion Criteria:
i. Female patients of age between 18 and 40 years undergoing gynecological surgeries (total abdominal hysterectomy, ovarian cystectomy, vaginal hysterectomy, myomectomy).
ii. ASA 1 and 2.
Exclusion Criteria:
i. ASA 3 and onwards as per the classification of the American Society of Anesthesiologists.
ii. Obstetric patients
iii. Patients who are allergic to study drugs.
iv. Patients undergoing general anesthesia.
Female patients undergoing gynecological surgery under spinal anesthesia will be recruited for the study.
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| DHQ | Sargodha | Pakistan |
Not provided
| Label | URL |
|---|---|
| Related Information | View source |
Not provided
Your study is a single-center anesthesia comparison trial.
There is no requirement to share individual participant data (IPD).
Unless you have a formal data-sharing mechanism (repository, request process, timelines), selecting Yes will create extra mandatory fields.
Not provided
Not provided
Not provided
Not provided
Not provided
A double-blind randomized controlled trial was conducted on 90 patients aged 18 to 40 years undergoing gynecological surgery after written consent and randomly divided into two groups of 45 each: Group N received Nalbuphine, and Group K received Ketamine. Patients with co-morbidities were excluded. Baseline hemodynamic parameters were recorded. Spinal anesthesia will be administered at L3-L4 or L4-L5. A dose of 1.2 mL of 0.75% hyperbaric bupivacaine was injected. Motor and sensory blocks will be assessed with the Bromage scale and a cold test. Following spinal anesthesia, patients will receive either Nalbuphine (0.07 mg/kg) or Ketamine (0.2 mg/kg) intravenously. The drugs, prepared in coded syringes, will be administered by an anesthetist blinded to group assignment. Shivering and hemodynamic variables were recorded. Sedation will be assessed by the Ramsay Sedation Score. Vomiting will be clinically monitored. If shivering reaches grade 3 or above, a rescue drug is given.
Not provided
Not provided
An independent outcome assessor was blinded to group allocation. This assessor was not involved in administering the anesthesia and had no knowledge of whether the participants received nalbuphine or ketamine. Incidence and grades of shivering, complications of study drugs such as vomiting and sedation, and the need for rescue drugs were evaluated by this blinded assessor to minimize bias.
|
|
| Participants assigned to this arm received injection ketamine. | Drug | After spinal anesthesia in a sitting position at L3-L4 or L4-L5 using a 25-gauge Quincke spinal needle, 1.2 mL of 0.75% (7.5 mg) hyperbaric bupivacaine was injected into the subarachnoid space. The Bromage scale and cold test by using a spirit swab will be used to evaluate the subarachnoid block for the desired motor and sensory blocks, respectively. After spinal anesthesia, the study drug ketamine (0.2 mg/kg) will be administered intravenously to group N, and oxygen will be given through a face mask at 4 liters per minute. |
|
|
Oxygen saturation will be monitored with a pulse oximeter probe.
| After spinal anesthesia, oxygen saturation was assessed at 5 minutes and then after every 10 minutes until 60 minutes. |
| Systolic blood pressure | Systolic blood pressure was measured with non-invasive blood pressure cuff. | After spinal anesthesia, systolic blood pressure was assessed at 5 minutes and then after every 10 minutes until 60 minutes. |
| Diastolic blood pressure | Diastolic blood pressure was assessed by non-invasive blood pressure cuff. | After spinal anesthesia, diastolic blood was assessed at 5 minutes and then after every 10 minutes until 60 minutes. |
| Temperature | Temperature was assessed by forehead temperature probe. | After spinal anesthesia, temperature was assessed at 5 minutes and then after every 10 minutes until 60 minutes. |
| Sedation | Sedation will be assessed by Ramsay sedation score as follows: Sedation score Sedation level
| Sedation was assessed for 1 hour post spinal anaesthesia. |
| Vomiting | Vomiting will be assessed clinically. | Vomiting was assessed for one hour post spinal anesthesia. |